Available to sourceHuman Prescription DrugOncology & Specialty

Epclusa (Velpatasvir and Sofosbuvir)

150 mg/1 / 37.5 mg/1 · Pellet

By Gilead Sciences, Inc.

NDC: 61958-2205
Route: Oral
Therapeutic class: Breast Cancer Resistance Protein Inhibitors [MoA], Hepatitis C Virus NS5A Inhibitor , Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor , Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], RNA Replicase Inhibitors [MoA]
Marketing category: NDA

Additional information

Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.

Request this medication

Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.

Related in Oncology & Specialty

See all →

Epclusa (Velpatasvir and Sofosbuvir)

Additional information

Request this medication

Related in Oncology & Specialty

Verzenio (abemaciclib)

Verzenio (abemaciclib)

Verzenio (abemaciclib)

Verzenio (abemaciclib)